Spyre Therapeutics Inc.
Organization details
- Legal name
- Spyre Therapeutics Inc.
- Former names
- Aeglea BioTherapeutics, Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Waltham
- Headquarters state / province
- Massachusetts
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- SYRE
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001636282
- EIN
- 46-4312787
- Wikidata ID
- Q45133036
Board of directors
-
Alison Frances Lawton · DirectorSince 2023
-
Cameron Turtle · Director · Chief Executive OfficerSince 2023
-
Hunter C. Smith · DirectorSince 2023
-
Ivana Magovcevic-Liebisch · DirectorSince 2023
-
Jeffrey W. Albers · DirectorSince 2023
-
Laurie Stelzer · DirectorSince 2023
- Since 2024
-
Michael Thomas Henderson · DirectorSince 2023
- Since 2023
-
Russell J. Cox · DirectorSince 2023
-
Sandra Milligan · DirectorSince 2024
- Since 2023
Chief executives
Director election results
Annual meeting of May 29, 2025. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
82.7%
Board connections
11 of this board's directors also sit on 23 other boards. 20 are in the same sector.
-
Dianthus Therapeutics Inc. Same sectorvia Alison Frances Lawton, Peter Evan Harwin and Tomas Kiselak
-
Oruka Therapeutics Inc. Same sectorvia Cameron Turtle, Peter Evan Harwin and Tomas Kiselak
-
Crescent Biopharma Inc. Same sectorvia Peter Evan Harwin and Tomas Kiselak
-
Damora Therapeutics Inc. Same sectorvia Cameron Turtle and Peter Evan Harwin
-
Gossamer Bio Inc. Same sectorvia Russell J. Cox and Sandra Milligan
-
Jade Biosciences Inc. Same sectorvia Peter Evan Harwin and Tomas Kiselak
-
Korsana Biosciences Inc. Same sectorvia Peter Evan Harwin and Tomas Kiselak
- via Mark C. McKenna and Michael Thomas Henderson
-
Viridian Therapeutics Inc. Same sectorvia Peter Evan Harwin and Tomas Kiselak
-
Zenas BioPharma Inc. Same sectorvia Peter Evan Harwin and Tomas Kiselak
-
Acrivon Therapeutics Inc. Same sectorvia Ivana Magovcevic-Liebisch
-
BridgeBio Oncology Therapeutics Inc. Same sectorvia Mark C. McKenna
-
Cogent Biosciences Inc. Same sectorvia Peter Evan Harwin
-
Freenome Inc. Same sectorvia Mark C. McKenna
- via Mark C. McKenna
-
Kymera Therapeutics Inc. Same sectorvia Jeffrey W. Albers
-
MBX Biosciences Inc. Same sectorvia Laurie Stelzer
-
NewAmsterdam Pharma Company N.V. Same sectorvia Mark C. McKenna
-
PMV Pharmaceuticals Inc. Same sectorvia Laurie Stelzer
-
ProQR Therapeutics N.V. Same sectorvia Alison Frances Lawton
- via Ivana Magovcevic-Liebisch
-
Sionna Therapeutics Inc. Same sectorvia Laurie Stelzer
-
X4 Pharmaceuticals Inc. Same sectorvia Alison Frances Lawton
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $441,932,902
- 94 sales by 7 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Oct 1, 2026 | King-Jones Heidy Officer (See Remarks) | Option exercise | +28,933 | $14.50 | $419,529 |
| Oct 1, 2026 | Cameron Turtle Director, Officer (Chief Executive Officer) | Open-market sale | −600 | $89.14 | $53,484 |
| Oct 1, 2026 | King-Jones Heidy Officer (See Remarks) | Open-market sale | −400 | $89.24 | $35,696 |
| Oct 1, 2026 | Cameron Turtle Director, Officer (Chief Executive Officer) | Open-market sale | −2,683 | $90.10 | $241,738 |
| Oct 1, 2026 | Burrows Scott L Officer (Chief Financial Officer) | Option exercise | +7,500 | $14.50 | $108,750 |
| Oct 1, 2026 | King-Jones Heidy Officer (See Remarks) | Open-market sale | −16,605 | $90.35 | $1,500,262 |
| Oct 1, 2026 | Cameron Turtle Director, Officer (Chief Executive Officer) | Open-market sale | −2,638 | $91.49 | $241,351 |
| Oct 1, 2026 | Burrows Scott L Officer (Chief Financial Officer) | Open-market sale | −600 | $89.07 | $53,442 |
| Oct 1, 2026 | King-Jones Heidy Officer (See Remarks) | Open-market sale | −7,228 | $91.35 | $660,278 |
| Oct 1, 2026 | Cameron Turtle Director, Officer (Chief Executive Officer) | Open-market sale | −3,989 | $92.31 | $368,225 |
| Oct 1, 2026 | Burrows Scott L Officer (Chief Financial Officer) | Open-market sale | −1,500 | $90.27 | $135,405 |
| Oct 1, 2026 | King-Jones Heidy Officer (See Remarks) | Open-market sale | −2,100 | $92.70 | $194,670 |
| Oct 1, 2026 | Cameron Turtle Director, Officer (Chief Executive Officer) | Open-market sale | −4,990 | $93.37 | $465,916 |
| Oct 1, 2026 | Burrows Scott L Officer (Chief Financial Officer) | Open-market sale | −2,100 | $91.92 | $193,032 |
| Oct 1, 2026 | King-Jones Heidy Officer (See Remarks) | Open-market sale | −2,600 | $93.46 | $242,996 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Spyre Therapeutics Inc.
Who is the CEO of Spyre Therapeutics Inc.?
Cameron Turtle is Spyre Therapeutics Inc.'s Chief Executive Officer.
How many directors are on Spyre Therapeutics Inc.'s board?
Spyre Therapeutics Inc.'s board has 12 directors: Alison Frances Lawton, Cameron Turtle, Hunter C. Smith, Ivana Magovcevic-Liebisch, Jeffrey W. Albers, Laurie Stelzer, Mark C. McKenna, Michael Thomas Henderson, Peter Evan Harwin, Russell J. Cox and 2 others.
Are Spyre Therapeutics Inc. insiders buying or selling shares?
Over the last 12 months, Spyre Therapeutics Inc. insiders made no open-market purchases and sold $441.9 million of shares in 94 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="spyre-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.